3: MDT collaboration in NSCLC - Aligning oncologists, nurses, and patients to enhance EGFR inhibitor treatment pathways and supportive care

Helena Ullgren (Clinical Nurse Leader, Karolinska Institute, Sweden), Elin Backman Stålnacke (Oncology Contact Nurse, Karolinska Institute, Sweden), Dr Pascale Tomasini (med onc) and Gini Harrison (UK patient), discuss the critical role of the multidisciplinary team (MDT) in managing patients with EGFR-mutated non-small cell lung cancer (NSCLC), with a strong focus on patient-centered care, communication, and shared decision making.

The panel highlights that effective care requires close collaboration between oncologists, nurses, and other specialists, alongside active involvement of the patient. Clear, consistent communication across the team is essential to ensure patients understand their treatment options, expectations, and potential side effects.

A key theme is the importance of shared decision making, while recognising that patients have different preferences for involvement and may need guidance and support when navigating complex treatment choices.

From the patient perspective, the discussion emphasises that treatment impact goes beyond clinical outcomes, including, quality of life and daily functioning, “time toxicity” (time spent on treatment and hospital visits) and real-world impact of side effects, which are often not fully captured by clinical grading system.

Overall, this session underscores that holistic, coordinated, and patient-focused care is essential to optimise outcomes and support patients living with EGFR-mutated NSCLC.